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Introduction 
 
Osteosarcoma (OS) is the most common, non-
hematopoietic, primary malignant tumor of 
bone [1]. It is a high grade neoplasm with rapid 
growth and early metastasis [2]. Even though 
effective chemotherapy for patients with OS has 
indeed led to a significant improvement of clini-
cal outcome, between 30 and 50% of patients 
with non-metastatic disease of extremities still 
die from this neoplasia, in spite of having had a 
complete surgical removal of the tumor and 
intensive chemotherapy [3, 4]. Currently, many 
immunohistochemical markers and genetic pro-
teins have been studied, but with prognostic 
and therapeutic relevance doubtful [5-7]. 
 
The proto-oncogene c-kit is located in the long 
arm of chromosome 4 and encodes a trans-
membrane tyrosine kinase receptor that binds 
the ligand stem cell factor. The c-kit signal 
seems to play a central role in regulating normal 
cell differentiation and proliferation. Mutation of 
the c-kit gene results in a constitutive activation 
of the c-kit protein, and it has been well docu-
mented in many tumors, such gastrointestinal 
stromal tumors (GIST) and myelodysplastic syn-
drome [8]. C-kit expression has also been found 
in osteosarcomas [9], with a high percentage of 
positive staining [8], but with divergent results 
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Abstract: Biologic agents targeting oncogenes have encourage researchs trying to correlate the role of tyrosine kinase 
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imatinib mesylate (STI571) on proliferation and invasion of the human osteosarcoma cell line.A retrospective immu-
nohistochemical study was performed on archival formalin-fixed paraffin-embedded specimens from 52 patients with 
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in the Department of Pathology, Federal University of São Paulo. Only pre-chemotherapy specimens were analyzed. 
Strongly stained cytoplasm and membrane cells were taken as positive. Human osteosarcoma cells from line MG-63 
were incubated and the inhibitory effect of imatinib mesylate (STI571) on cell proliferation and invasion was studied. 
In 24 cases (46.15%), c-kit was expressed by the cells and c-kit-positive tumors exhibited lower necrosis post-
chemotherapy. No correlation was found between c-kit expression and overall and disease-free survival. Imatinib 
mesylate decreased the rates of cell growth of osteosarcoma cells in low doses and invasion in high doses C-kit-
positive tumors had worse response to chemotherapy and imatinib mesylate can play a role in blocking or decreasing 
the rate of growth of osteosarcoma cells, but not the invasive capacity of these neoplastic cells. These data sug-
gested that imatinib mesylate could be a therapeutic target of strategies against osteosarcoma tumors. Further stud-
ies are necessary to confirm this indication. 
 
Keywords: Osteosarcoma, c-kit, immunohistochemistry, in vitro assays, prognosis 
C-kit expression in human osteosarcoma and in vitro assays 
 
 
776                                                                                                       Int J Clin Exp Pathol 2011;4(8):775-781 
about the prognostic value of this expression 
[10-12]. Imatinib mesylate (IM), STI571, is a 
selective inhibitor of the enzymatic activity of 
several tyrosine kinases and is successfully 
used in the treatment of GIST with mutations in 
exons 9 and 11 of the c-kit gene [13, 14]. Until 
now, few studies on the effect of IM on cellular 
growth have been reported using cell culture 
[15]. We tried to analyze in our homogeneous 
cohort of patients, whether c-kit expression can 
predict the evolution of patients with osteosar-
coma and the effect of IM on proliferation and 
invasion of human osteosarcoma cell line. 
 
Materials and methods 
 
Fifty-two patients with high grade osteosarco-
mas were selected from the files of Department 
of Pathology at Federal University of Sao Paulo 
and Pediatric Oncologic Institute (GRAAC), be-
tween 2000 and 2005. These patients were 
treated according to the Study 2000 protocol 
guidelines (Tables 1 and 2). Only prechemo- 
therapy specimens were selected (Table 3). 
Table 1. Protocol for non-metastatic osteossarcoma* (Total time: 24 weeks) 
Weeks Evaluations and Procedures 
  Initial evaluation: local and torax NMR or CT, cintigraphy, local and torax X-ray, complete hemogram, 
TGO, TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation, pathology, 
genetics, tumor bank; BTF, U, Cr, biochemical tests (Na, K, Mg, Ca) 
0 CDDP DOXO 
3 AD IFO 
5 Cycle I - preoperative audiometry / cardiac evaluation 
6 CDDP DOXO 
  Orthopedics (consultation) 
9 AD IFO 
11 PREOPERATIVE EVALUATION local and torax NMR or CT, cintigraphy, local and torax X-ray, complete he-
mogram, TGO, TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation. 
12 SURGERY  EVALUATION: Pathology and Genetics 
15 CDDP DOXO 
18 AD IFO 
20 Cycle II - postoperative audiometry / cardiac evaluation 
21 CDDP DOXO 
24 AD IFO 
27-28 Final evaluation local and torax NMR or CT, cintigraphy, local and torax X-ray, complete hemogram, TGO, 
TGP, alkaline phosphatase, DHL, creatinine clearance, audiometry, cardiac evaluation. 
*Brazilian Cooperative Group for Treatment of Bone Tumors (GBCTTO), 1999. 
AD: adriamycin; CDDP: cisplatin; DOXO: doxorubicin; IFO: ifosfamide. 
 
Table 2. Drugs and doses used in the treatment of patients with high grade osteosarcoma 
Drugs Daily dose Total dose/m2 
CDDP 60 mg/m2 D1, D2 = 120 mg/m2 x 4 480 mg/m2 
DOXO 40 mg/m2 D1, D2 = 80 mg/m2 x 4 320 mg/m2 
IFO 2.7 g/m2 D1 - D5 = 13.5 g/m2 x 4 54 g/m2 
MESNA 600 mg/m2 hour 0, 3, 6 e 12 2.7 g/m2/day 
  Obs.: hour 12 Mesna tablets v.o. (optional)   
AD: adriamycin; CDDP: cisplatin; D1: ; D2: ; DOXO: doxorubicin; IFO: ifosfamide; MESNA: sodium 2-mercaptoethane 
sulfonate 
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Immunohistochemistry 
 
All identifiable archival material was retrieved 
from the Department of Pathology. In all cases, 
paraffin blocks from the primary site were se-
lected. Bone specimens were decalcified with 
nitric acid (7.5%) and after that, were rinsed in 
water (30 min) and immersed in sodium bicar-
bonate (5%, 24 h). Sections (4 µm) were cut, 
deparaffinized, and rehydrated. Diluted (1:500) 
polyclonal anti-CD117 antibody (pAb; DAKO, 
A4502, Carpinteria, CA, USA) was used to stain 
the sections to assess expression of c-kit pro-
tein. Antigen in the sections was retrieved with 
high-pressure cooking treatment (5 min). En-
dogenous peroxidase was blocked with hydro-
gen peroxide (H2O2), into which the slides were 
immersed (5 times, 5 min, one at a time). Incu-
bation (4°C, overnight) of the sections with the 
anti-CD117 pAb was followed by rinsing (30 
min) with phosphate-buffered saline (PBS). 
Thereafter, the slides were incubated (37°C, 15 
min) with the streptavidin-biotin-peroxidase 
complex (biotinylated peroxidase; Dako A/S) 
(biotinylated antibody), rinsed again in PBS and 
incubated (15 min) in strepatavidin-biotin-
peroxidase reagent. Color was developed by 
incubating (37°C, 5 min) the slides with 3, 3-
diaminobenzidine tetrahydrochloride (Sigma) in 
presence of H2O2 (0.05% in PBS). Slides were 
then rinsed with tap water, counterstained (5 
min) with Harris hematoxylin, rinsed in ammonia 
water, dehydrated, and coverslipped. A case of 
gastrointestinal stromal tumour (GIST) with 
known overexpression of c-kit served as the 
positive control. An appropriate negative control 
was used throughout. All slides were examined 
blindly by two independent pathologists.  
 
The specimens were scored according to both 
the percentage of positively stained tumor cells 
and their immunostaining intensity. The immu-
nostaining intensity was codified as negative 
(0), weak (+), moderate (++), and strong (+++) 
expression. Only slides with moderate (++) and 
strong (+++) expression were considered as 
positive. Specimens with moderate expression 
showed cytoplasm stained in a diffuse pattern. 
Specimens with strong protein expression exhib-
ited both cytoplasm and membrane stained in a 
diffuse pattern. A cut-off point of 10% was used.  
 
In vitro assays 
 
Cell culture. MG-63 cell line was incubated 
(37ºC) in a humidified CO2-enriched (5%) atmos-
phere. Cells were cultured in RPMI-1640 me-
dium (Invitrogen, Burlington, Ontario, Canada), 
supplemented with heat-inactivated fetal bovine 
serum (FBS; 5%), fungizone (1%), and penicillin-
streptomycin (1%) purchased from Invitrogen 
(Burlington, Ontario, Canada). Cells were cul-
tured as a monolayer in 25 cm2 flasks (Fisher, 
Whitby, Ontario, Canada) and evaluated twice a 
week, at every media change, for normal growth 
by phase-contrast microscopy. The culture was 
grown to confluence and underwent a treatment 
(37ºC) with trypsin (0.05%) in ethylene diamine 
tretraacetic acid (EDTA; Fisher) and washed in 
RPMI-1640 medium (7 ml) before being centri-
fuged (120 x g, 10 min) to form a pellet. Cells 
were then suspended in RPMI-1640 medium (1 
ml) and counted using the Trypan Blue-dye ex-
Table 3. Data of 52 patients treated for high 
grade osteosarcoma 
Age (years) Range 5 a 29 
Median 15 
Follow up 
(months) 
Range 9.2 a 96.8 
Median 44.7 
Sex n % 
Male 
Female 
29 56 
23 44 
Localization of primary tumor n % 
Femur 
Tibia 
Humerus 
Radius 
Ilium 
Polyostotic 
Other 
30 58 
15 29 
3 13 
1 1.92 
1 1.92 
1 1.92 
1 1.92 
Metastasis at diagnosis n % 
Yes 
No 
16 31 
36 69 
Responders n % 
No 
Yes 
Not available 
33 63 
17 32 
2 4 
Survival n % 
Alive 
Dead 
Not available 
25 48 
26 50 
1 2 
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clusion test.  
 
Invasion assay. A modified Boyden chamber 
consisting of a polyethylene terephthalate mem-
brane (PET) with 8-μm diameter pores, pre-
coated with Matrigel, an artificial basement 
membrane (Beckton Dickenson Labware, Bed-
ford, MA, USA), was used as previously de-
scribed [13] to assay for cell invasive ability. A 
PET membrane without Matrigel was used as a 
control.  
 
Cells (1.25x105) suspended in RPMI-1640 me-
dium with FBS (0.1%) were added to the upper 
chamber. RPMI-1640 medium with FBS (10%) 
was added to the lower chamber, which acted 
as a chemoattractant, to obtain the baseline 
invasive ability of the cell lines. Inhibition of cell 
invasion was assayed by adding IM (50 μM) to 
the RPMI-1640 medium supplemented with 
FBS (10%) in the upper chamber. MI concentra-
tion (50 μM) for 50% inhibition of cell invasion 
(IC50) was semi-quantitativelly estimated. All 
cells were killed with a concentration of 1000 
μM, which would make the invasion measure-
ment not feasible. Half of the cells were killed 
(letal dose of 50%) with a concentration of 100 
μM, which was still too strong to measure inva-
sion. A significant effect of cell invasion was not 
observed with a concentration of 10 μM. There-
fore, regarding the distinct effects caused by IM 
doses of 100 e 10 μM on cell invasion, 50 μM 
was considered a convenient concentration, 
which neither killed nor destroyed the cells yet 
displaying a cytostatic effect.  
 
Non-invading cells were removed from the up-
per chamber by gently wiping the membrane 
surface with a moist cotton swab. The mem-
branes were removed and stained with a Diff-
Quick staining kit, which stains cell nuclei pur-
ple and cytoplasm pink. Stained cells were ran-
domly counted under microscope in 20 high-
powered fields. Only cells whose nuclei had 
completely invaded through the membrane 
were counted. Each experimental condition, 
including the control, was performed in triplicate 
and the average number of invading cells was 
then calculated for all experimental conditions.  
 
Percent invasion was determined for each cell 
line under each experimental condition using 
the following formula: % invasion = 100 x (mean 
number of cells invading through the Matrigel 
membrane) / (mean number of cells migrating 
through the control PET membrane). The cell 
lines were then ranked according to their inva-
sive ability.  
 
Proliferation assay 
 
The sulforhodamine-B (SRB)-based assay kit 
(TOX-6, Sigma-Aldrich) was performed as per 
the National Cancer Institute protocol [15]. 
Briefly, 2.5x103 cells of the MG-63 line were 
seeded into each well, in a minimum of six 
wells. A row of 8 wells exposed only to the RPMI-
1640 medium was used as a control. Twenty-
four hours following cell seeding, IM was added 
to the experimental wells where cells were al-
lowed to incubate (24 h). IM concentrations 
were 1000, 100, 10, 1, 0.1, 0.01, and 0.001 
μM [14]. After incubation, cells were fixed to the 
bottom of the wells using a trichloroacetic acid 
(TCA) solution (50%, 1 h, 4°C). Plates were then 
rinsed with distilled water, to remove TCA and 
medium, and air dried. The SRB dye was added 
to each well and allowed to stain (25 min). The 
dye was then removed by washing with acetic 
acid solution (10%) and allowed to air dry. The 
dye, which was incorporated into the fixed cells 
at the bottom of the wells, was solubilized in a 
tris-hydroxymethyl-amino-methane solution (10 
mM) for quantification. The absorbance values 
for the solute were read using a microplate 
reader (λ= 510 nm). This procedure allowed a 
comparison between the proliferation rates of 
cells exposed to IM at given doses and the con-
trol over 48 h.  
 
Statistical analysis 
 
Kaplan Meier and log rank tests were utilized to 
compare the overall survival rates between pa-
tients with positive versus negative staining for 
c-kit. All analyses were performed using the 
Prism 4.0 program (GraphPad Software Inc., 
San Diego, CA, USA). Differences between inva-
sion rates for the MG-63 cell line under experi-
mental conditions were determined using the 
ANOVA test. The growth rates with and without 
IM were determined using the Student’s t-test. A 
p value of less than 0.05 was considered to be 
statistically significant in these tests. Calcula-
tions were computer-based (SPSS 11.5, SPSS 
Inc., Chicago, IL, USA). 
 
Results 
 
Twenty-four of the 52 pediatric patients 
(46.15%) showed immunoexpression of c-kit 
(Figure 1). These expressions were statistically 
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correlated with bad response to chemotherapy 
(p=0.0355). No correlation with c-kit positivity 
and recurrence, death, and metastases at diag-
nosis was observed. No correlation between c-
kit immunoexpression and poor survival 
(p=0.643) was observed when only non-
metastatic pediatric patients at diagnosis (15 
cases) were analyzed isolatedly (Figure 2). Addi-
tion of IM inhibited growth of osteosarcoma cell 
line in doses of 1000, 100, 0.1, 0.01, and 
0.001 μM (Figure 3) and cell invasion in doses 
of 50 μM. 
Discussion 
 
A strong immunoexpression of c-kit was found 
in osteosarcomas (46.15%), comparable to 
those reported by Entz-Werle et al [10] (57%), 
Wei et al [12] (62,5%), and Smithey et al [9] 
(39%) Our positive cases showed a statistically 
high correlation with bad response to chemo-
therapy. However, such high expression was not 
correlated with overall survival and disease-free 
survival. In the literature, correlation between 
expression of c-kit and necrosis post-
chemotherapy was reported only by Sulzbacher 
et al [11], who found no correlation of these 
variables, and overall and disease-free survival. 
Although these authors studied a considerable 
number of patients (100) with osteosarcoma, 
15% of the tumors were axial. Also, the patients 
were treated with four different protocols, and 
only 20% of the cases expressed the protein c-
kit. The use of different methodologies to evalu-
ate c-kit expression and the nonhomogeneous 
cohort may explain the different results. More-
over, in the present study, patients who overex-
pressed c-kit protein did not show a higher prob-
ability to develop metastases than c-kit-negative 
patients. 
 
Sulzabacher et al [11], Entz-Werle et al [10], 
and Wei et al [12] searched for mutations in the 
c-kit gene, but none could be found. Since the 
essential of studies on the mutation status of c-
kit gene is evaluation of tumor response to IM, 
we decided to study the ability of IM to inhibit 
cell growth in the osteosarcoma cell line in vitro. 
ST1571 inhibited cell growth in the osteosar-
coma cell line in doses of 1000, 100, 0.1, 0.01, 
and 0.001 μM and cell invasion in doses of 50 
μM. Yoshitani et al [15] demonstrated cell 
growth inhibition in the rat osteosarcoma cell 
line by IM in a concentration of 10 μM, the maxi-
mal tolerated concentration. Knowledge on the 
capacity of invasion by tumor cells is important 
both to evaluate the ability of these cells to 
cross the basal membrane and to calculate the 
ability of tumor cells to develop metastases. Our 
study showed that IM inhibited invasion of os-
teosarcoma line cells only in high concentration 
(50 μM).  
 
Conclusions 
 
C-kit protein is strongly immunoexpressed in 
human osteosarcoma and the positive cases 
indicate a group of patients who will have a poor 
Figure 1. Immnoexpression of c-kit. - Membranous 
and cytoplasmic staining. 
Figure 2. Overall survival and c-kit expression (only 
non-metastatic patients) 
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response to chemotherapy. The c-kit gene might 
be involved in osteosarcoma carcinogenesis 
since this tumor immunoexpress the protein 
and ST1571 could inhibit the growth of human 
osteosarcoma cell line in vitro, even at low 
doses. Seeing that IM could inhibit the invasion 
of cell lines in vitro, only in high doses, and that 
c-kit expression do not influence the tumor ca-
pacity to metastasize, we can suggest that c-kit 
gene is not involved in the progression of this 
disease.  
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